Since becoming law in 2010, the ACA has expanded government-provided health insurance to add more than 15 million Americans who previously were uninsured. 1 While many people feel that covering the uninsured will be Mr. Obama's greatest accomplishment as president, there are other important changes sweeping through the U.S. healthcare system, also as a result of Obamacare. The goal is to fundamentally improve the average quality of medical care that patients receive, while at the same time decreasing the cost of healthcare. In other words, to increase the costeffectiveness or "value" of physician clinical performance, from the patient point of view.
In this special article, I describe the value movement in healthcare from the point-of-view of a physician who is familiar with American and Japanese clinical practice. I am board-certified in the primary-care specialty called "family medicine", which combines internal medicine and pediatrics. Currently I teach clinical medicine to resident physicians in a medium sized (350 bed) Japanese hospital, and I work with other hospitals in Japan who use outcomes research and reporting to improve quality of care. Every year, I
work for several months in American clinics, most recently for the Indian Health Service in central Oklahoma.
II. Healthcare Quality and Cost in Different Countries
Every two years, the Paris-based Organization for Economic Cooperation and Development (OECD) publishes data that compares healthcare statistics between various countries. In particular, the following OECD graph creates concern and embarrassment for politicians and health officials in the United States:
This graph highlights the fact that the U.S. has the most expensive healthcare system in the world but with life expectancy rates significantly less than other developed countries. Only developing countries in Eastern Europe, South America and Asia have life expectancy rates less than the U.S. rates. If one chooses infant mortality rates as the outcome, then the results are very similar. For example, in 2011 the Japanese infant mortality rate was 2.3 deaths per 1000 births, whereas in the U.S. it was 6.1 per 1000 births. 3 Yet the U.S.
spends greater than 200% the amount that Japan spends on healthcare per capita, when one counts both private and public expenditures. Compared to other countries, the U.S. is truly a healthcare "outlier".
III. How did America Become the Biggest "Healthcare Outlier" among the Developed
Countries?
One hypothesis is that high U.S. spending on healthcare has reduced U.S. mortality rates as a function of time, more than in other developed countries, such as Japan. One might imagine how many years ago, the U.S. started from a worse position in terms of health status, because of its diverse, multi-ethnic, immigrantbased population. As a result, high healthcare spending was necessary in the U.S, for it to "catch-up" to the mortality benefits of healthy lifestyles seen in more traditionally based nations, such as Japan. Healthy lifestyles cost very little, after all. However, as data from the Institute for Health Metrics (IHME) shows in Figure 2 below, this has not been the case.
From 1990 to 2013, despite roughly double per-capita healthcare spending in the U.S., the increase in life in expectancy in Japan actually exceeded the increase in the U.S by about 10%: +4.3 years in Japan vs. +3.7 years in the U.S. IHME studied the contribution of major disease groups to the life expectancy changes over the past 25 years, as shown schematically in Figure 2 by the color legend. Cardiovascular disease (CVD) is the largest cause of death in all developed countries, and mortality rates have dropped by a remarkable 35% to 40% over the past 25 years (IHME graph not shown). The U.S. was the largest beneficiary of CVD mortality reductions, in absolute terms, but the relative effect was not high enough to move American life expectancy past the 80 year mark. Surprisingly, Japan had higher gains in cancer-related life expectancy than the U.S. did (using a composite outcome of all neoplasm types), and they achieved a broad base of small improvements in other disease categories. On the other hand, the U.S. failed to achieve a broad base of gains -other than in CVD, oncology, injuries and HIV disease, as it failed to "catch-up" to Japan over the past 25 years. (It was also one of the only developed countries to lose life expectancy (¹0.3 years) as the result of mortality rate increases over time in a single IHME disease category: substance abuse and mental health.)
Results are similar when one uses IHME data to compare U.S. : obesity and diabetes; : heart disease;
: chronic lung disease; and : disability. 
V. Defining Value in Healthcare
For the Obama government, improving healthcare IT was only "clearing the road" for other bigger changes.
Starting around 2010, a powerful combination of university scholars, health insurance executives and government leaders began "waking up" -pushing American healthcare into the 21 st century. Their goal was to create "value for the patient", rather than the current system of creating value mostly for physicians, hospitals and life science companies.
But what exactly is better "Value" in healthcare? To begin with, even in the U.S., nearly everyone agrees that healthcare systems must achieve these three basic goals: (1) better care for individuals, (2) better health for populations and (3) lower costs. 5 Value simply unites these 3 goals into one single calculation: patient health outcomes achieved per dollar spent.
In business, value is defined as the results achieved (outputs) relative to the costs required (inputs), which is a measure of efficiency. Professor Michael Porter at Harvard Business School is the acknowledged visionary and architect behind American value-based healthcare reform. Harvard's website calls Porter "the founder of the modern strategy field and one of the world's most influential thinkers on management and competitiveness." 6 Healthcare reform is a new central focus of Dr. Porter's academic and consulting work. He writes that:
"It is value for the patient that is the central goal, "Pay for Reporting" and PQRS: The American Quest for Value in Healthcare not value for other actors per se. In a wellfunctioning health care system, the creation of value for patients will determine rewards for all system actors." 7 Porter's "system actors" are physicians and hospitals, insurance companies and government payers. The "rewards", which Porter refers to, are financial ones.
It's surprising that one of the world's most respected corporate strategy consultants, Michael Porter, promises doctors and hospital executives that good "business sense" focuses on increasing "value for the patient" (instead of maximizing only patient volume or business profits). "Value should be defined around the customer, not the supplier." 7 In healthcare the patient is the customer and the physician is the supplier. During 2010, in a series of policy articles published in the New England Journal of Medicine, Professor Porter worked hard to change the minds of physicians who were uncomfortable with a healthcare policy based on value or efficiency. At the same time, however, the government was already "rolling out" Obamacare, which (to many physicians' surprise!) embraced the following value concepts, originally from Porter:
1. Profitability+is not a reliable indicator of value in healthcare because of flawed reimbursement and lack of competition based on actual results. 7 2. Every (healthcare) provider can begin to measure the outcomes in the medical conditions it serves, and track progress versus past performance. 4. Outcomes highlight and validate opportunities for value enhancing cost reduction. 5. The most powerful single lever for reducing cost is improving outcomes. 6. Cost-reduction, without regard to outcomes achieved, is dangerous and self-defeating (in healthcare). 10 In business, people say "quality is free". But how does this work in healthcare? According to Porter, it means spending more money on "high-value" services, such as prevention and appropriate early-stage specialty care, which will then decrease the intensity and volume of late stage care -so the net cost over the full cycle of care actually drops.
An important recent example is Hepatitis C. The U.S. government is already paying for the full cycle of Hep C care delivered to Native Americans under the Indian Health System (from the personal experience of the author). From patients' point-of-views, the quality benefit of early Hep C diagnosis is large. The outcome benefit to the Indian population is even larger, as the epidemic may extinguish in the long run. As far as costs, although antiviral treatments are expensive, cirrhosis and hepatocellular carcinoma are terrible complications. By looking at both the numerator and denominator in the value calculation, outcomes are higher, costs measured over the full cycle of care are lower, and so Hep C screening programs greatly increase value.
(However, with disease screening, there may be exceptions, such as universal PSA-based prostate cancer screening, when early diagnosis can cause more QOL harm than good, while unnecessarily increasing the frequency of early stage treatments.)
In conclusion, the ideal healthcare system improves outcomes while simultaneously reducing costs, which is to say: the best healthcare maximizes value for the patient. Again, very few can argue with this statement.
So why is it still controversial among physicians?
VI. "Life in the Gap" between Volume-based and Value-based Healthcare Just three years ago, "first curve" dynamics rewarded U.S. doctors and hospitals who increased volume of services provided and maximized fee-for-service payments. If Obamacare "Part 2" works, the second curve will reward value. The most important strategic issue for hospitals and physicians is to transform from "firstcurve" to "second-curve" practice-models. The American Hospital Association refers to this transformation period as "Life in the Gap". This reward for value has been a step-wise process. XII. Physician Feedback: Critical "Backlash" As far as the limited negative coverage in NEJM, the to calculate the "value ratio". The program adjusts (increases or decreases) current-year payments to hospitals, as a function of value-ratios calculated from quality/cost data that is 2 years old. Then by 2017, the Affordable Care Act (Obamacare) rules that the government must adjust payments to all physicians (even small private clinic doctors) using their government-computed value ratios. Clinics with high performing doctors (high quality and low cost) will get paid maximum fees for each medical service delivered; clinics with low-performing doctors (low quality and high cost) will get paid minimum fees.
Clinics whose doctors perform in the middle (high quality and high cost; or low quality and low cost) will probably see their payments unchanged. Preliminary data suggest that 80% to 90% of doctors perform in the middle, 10% to 15% perform at the high level, and only 5% or less of doctors are low-performing. Fee adjustments are small to start with -the difference between maximum fees and minimum fees is less than 10%. However, the U.S. government is expected increase adjustments as necessary until there is genuine evidence that the program is causing significant increases in "high-value" care.
XIV. Conclusion
In summary, there is a quiet revolution going on in U.S.
healthcare; and as a result, Americans may someday achieve the "Triple Aim" of healthcare: (1) better care for individuals, (2) better health for populations and (3) lower costs. The early success of this movement depends on the government "pushing" the change onto
American doctors, by changing their payment system. First the government financially rewarded participation in PQRS, and then later -starting in 2015 -it is punishing doctors (financially) who refuse to participate.
In business, disruptive change spreads rapidly and globally. Disruptive change can bankrupt whole industries which are slow to change to the new model. The ACA (Obamacare) is the most disruptive change to
American medical practice since President Johnson signed Medicare into law in 1966. The ACA attempts to prevent a Medicare financial "meltdown", caused by exploding medical costs and the rising elderly population. Japan faces its own possible future healthcare financing crisis, as it also pays for the ever rising cost of geriatric medical care. The Japanese healthcare community might pay close attention to this "disruptive" change in American healthcare.
